Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23 ( SAN DIEGO June 21 2007 /PRNewswire-F...)

HOME >> MEDICINE >> TECHNOLOGY

Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23

SAN DIEGO, June 21, 2007 /PRNewswire-FirstCall/ -- Orexigen(TM) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of central nervous system disorders with an initial focus on obesity, today announced that the Company will present data about its lead obesity product candidate Contrave(TM) and its effect on markers of cardiovascular disease (visceral fat, serum cholesterol, and triglycerides) and insulin-resistance. The findings come from additional analyses of the Phase IIb multi-center clinical trial of Contrave. The data will be presented on Saturday, June 23rd, 6:00-7:15 pm and Monday, June 25th, 2007 at the 67th Annual Scientific Sessions of the American Diabetes Association (ADA) in Chicago, IL. Contrave data can be found in category 20B, poster number 45LB entitled, "Weight Loss with Bupropion and Naltrexone Improves Markers of Insulin-Resistance."

Contrave is a proprietary fixed dose combination of bupropion SR (sustained release) and Orexigen's novel formulation of naltrexone SR in a single tri-layer tablet. In a Phase IIb multi-center clinical trial, Contrave demonstrated statistically significant weight loss at 24 weeks compared to bupropion SR alone, naltrexone IR (immediate release) alone, and placebo. Contrave is now being studied in two separate multi-center Phase III studies, one of which is designed to further assess its safety and efficacy in obese subjects with Type II diabetes.

About Orexigen Therapeutics

Orexigen(TM) Therapeutics, Inc. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, with an initial focus on obesity. Orexigen's lead combination product candidates targeted for obesity are Contrave(TM), which is in Phase III clinical trials, and Empatic(TM) (formerly Excalia(TM)), which is in a Phase IIb clinical trial. Both product candidates take ad
'"/>

Page: 1 2 3
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
9. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
10. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
11. Barrier Therapeutics Announces Liarozole Phase 2/3 Study Results in Lamellar Ichthyosis

Post Your Comments:

(Date:11/6/2009)..., NATICK, Mass., Nov. 6 ... announced that it has reached an agreement in pri...elated to product advisories issued by its Guidant...uct sales occurred prior to Boston Scientific,s 20... had previously disclosed an investigation by the ...

(Date:11/6/2009)..., WINNIPEG, Manitoba, Nov. 6 With...arack Obama has set his sights on cutting name-bra...are patients who fall into the "Part D" coverage g...vocates rave about the potential cost-cutting and ... Yet some of the most powerful lobbyists want a re...

(Date:11/6/2009)..., RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswir...advancing orally-available antiviral therapeutics ...dates on the development of the company,s lead ant...ization (WHO) and the Global Health Security Initi...l agent being developed for the treatment of small...

[0] Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant [0] Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole'[0] Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox

...plore the Efficacy of Novel Proteasome Inhibitor i...ltiple Myeloma, SOUTH SAN FRANCISCO, Calif. and N...rch Consortium (MMRC) and Proteolix, Inc. today,an...ulti-center Phase 2,clinical trial to study Proteo...arfilzomib (PR-171), in patients with relapsed and...

...ade Possible by Early Investment by Cystic Fibrosi...SDA, Md., Aug. 15 Gilead Sciences,Inc., one of th... Parion,Sciences, Inc., a development-stage pharma...elop Parion 680, a compound that could become an i...cystic fibrosis. This product was,identified as pa...

Other Medicine Technology:The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2 The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3 The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4 Promising Cystic Fibrosis Compound on Track for Development 2

The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma Promising Cystic Fibrosis Compound on Track for Development

(Date:11/8/2009)..., "One victory does not mean the battle is won,.... 7 In a vote of 240-19...pinski-Smith Amendment to prohibit abortion mandat...r. ,, Americans United for Life Action Presiden...f this amendment is a victory for the pro-life Ame...

(Date:11/8/2009)..., WASHINGTON, Nov. 8 ... Director, Operation Rescue Insurrecta Nex. ,,...try have been fighting to keep child-killing by ab..., Mr. Terry states: "This is a great first step t...ut we have a lot of fighting ahead of us. Our rejo...

(Date:11/7/2009)..., WASHINGTON, Nov. 7 ...th Insurance Plans (AHIP), released the following ..., "Health plans strongly support comprehensive he...discussion by proposing a complete overhaul of how...we proposed guaranteed coverage, elimination of pr...

(Date:11/7/2009)..., HOUSTON, Nov. 7 Calling this a...ation (AMA), the AMA President J. James Rohack, M....ysicians from all state and medical specialty soci...cy-making meeting, where health system reform will....com/cgi-bin/prnh/20081209/AMALOGO ) ,, "Over...

(Date:11/7/2009)..., WASHINGTON, Nov. 7 ... press availability this afternoon following a Dem...annon Caucus Room. Below are the Speaker,s openin... Yes, it was a great occasion for us to receive th...we will be making history with our vote and making...

Breaking Medicine News(10 mins):Health News:Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People 2 Health News:AHIP Statement on House Passage of H.R. 3962 2 Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2 Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2

[0] Americans United for Life Action Comments on Passage of Pro-Life Amendment: Bipartisan Pro-life Majority Reflects the Will of the American People [0] Stupak Amendment Passes in Final House 'Health Care' Bill. A First Step to Victory, but Many Battles Ahead. We Must Rejoice With Caution.[0] AHIP Statement on House Passage of H.R. 3962 [0] AMA President Kicks Off AMA Meeting Focused on Health Reform [0] Pelosi Remarks Following House Democrats' Meeting with President Obama

...s., Oct. 20 Psychemedics,Corporation (Nasdaq: PM...ed,the company as Vice President, Controller., Ra...l financial,reporting activities, as well as the f..., Ray has served as Director of International Fina...

...of Silicon Merges High-Performance Data Conversion...ompression, SANTA CLARA, Calif., Oct. 20 Samplif...on solutions, today announces its move,from intell...se: Samplify Announces SAM1600 Family) Samplify ma...

... OCI Adds Two National Sales Repre... Denver, CO (PRWEB) October 20, 2008 -- OCI, ...risk management , HR and employee benefits leade...Lenox, based in Chicago, Illinois., , ,“Kell...

... The Florida Academy of Cosmetic D...ery Competition to Sarasota cosmetic dentist Dr. C... Florida (PRWEB) October 20, 2008 -- The Sarasota...y Competition., , ,The FACD Smile Gallery competit...

...s a member of PPI class for treatment for GERD and... OSAKA, Japan, Oct. 20 Takeda Pharmaceutical Com...a Global Research and,Development Center, Inc., a ...o complete its review of the TAK-390MR New,Drug Ap...

...sts at the Gladstone Institute of Neurological Dis...found that complete or partial removal of an enzym...ive deficits in a mouse model of Alzheimer,s disea... disease as well as a novel therapeutic strategy. ...

Other Medicine News:Health News:Raymond J. Ruddy Joins Psychemedics Corporation As Top Financial Officer 2 Health News:Samplify Evolves Business Model From IP Developer to Semiconductor Supplier; Now Targets Multi-Billion Dollar Market 2 Health News:Employee Benefits and Risk Management Solutions Provider OCI Appoints Two New Representatives to Its Sales Team 2 Health News:Sarasota Cosmetic Dentistry Practice Wins Big At FACD 2 Health News:FDA Adds Three Months to Review of Takeda's New Drug Application for TAK-390MR 2 Health News:Gladstone scientists identify role of fatty acids in Alzheimer's disease 2

Raymond J. Ruddy Joins Psychemedics Corporation As Top Financial Officer Samplify Evolves Business Model From IP Developer to Semiconductor Supplier; Now Targets Multi-Billion Dollar Market Employee Benefits and Risk Management Solutions Provider OCI Appoints Two New Representatives to Its Sales Team Sarasota Cosmetic Dentistry Practice Wins Big At FACD FDA Adds Three Months to Review of Takeda's New Drug Application for TAK-390MR Gladstone scientists identify role of fatty acids in Alzheimer's disease

... reference laboratory and a worldwide leader in in... offers an extensive test menu of highly complex a...athology. Owned by the University of Utah, ARUP La...nation's university teaching hospitals and childre...

Medicine Products:

bcl-2/JH, t(14;18) Translocation by PCR, Tissue bcl-1/JH, t(11;14) Translocation by PCR, Paraffin B-Cell & T-Cell Comprehensive Clonality Assessment, Fluid B-Cell & T-Cell Clonality Assessment by PCR, Fluid

( SAN DIEGO June 21 2007 /PRNewswire-F...)Orexigen Therapeutics to Present Data on Contrave Impact on,Visceral Fat and Insulin Resistance at American Diabetes,Association 67th Scientific Sessions in Chicago June 23,Health